NCT02707978

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

F 18 T807 Tau PET Imaging of Frontotemporal Dementia

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Tammie L. S. Benzinger, MD, PhD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate tau distribution in the brain of subjects with: FTD caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic FTD, normal controls.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	F 18 T807	Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Timeline

• Start date: 2017-09-30
• Primary completion: 2020-09-30
• Completion: 2020-12-30
• First posted: 2016-03-14
• Last updated: 2024-03-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study